2.21
-0.14(-5.96%)
Currency In USD
| Previous Close | 2.35 |
| Open | 2.29 |
| Day High | 2.32 |
| Day Low | 2.15 |
| 52-Week High | 3.29 |
| 52-Week Low | 0.13 |
| Volume | 3.65M |
| Average Volume | 18.77M |
| Market Cap | 276.16M |
| PE | -1.46 |
| EPS | -1.51 |
| Moving Average 50 Days | 1.07 |
| Moving Average 200 Days | 0.96 |
| Change | -0.14 |
If you invested $1000 in Vor Biopharma Inc. (VOR) since IPO date, it would be worth $58.93 as of July 30, 2025 at a share price of $2.21. Whereas If you bought $1000 worth of Vor Biopharma Inc. (VOR) shares 2 years ago, it would be worth $453.8 as of July 30, 2025 at a share price of $2.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
GlobeNewswire Inc.
Jul 21, 2025 12:30 PM GMT
- New board members bring decades of experience in company building, corporate strategy, commercialization, and business development CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company t
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Jul 18, 2025 8:00 PM GMT
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer
GlobeNewswire Inc.
Jul 17, 2025 12:30 PM GMT
Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple regulatory approvals in China; brings deep U.S. and global development experience to support Vor Bio’s new development focus and ex